RT Journal Article
SR Electronic
T1 Detection of SARS-CoV-2 variant 501Y.V2 in Comoros Islands in January 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.08.21254321
DO 10.1101/2021.04.08.21254321
A1 Agoti, Charles N.
A1 Githinji, George
A1 Mohammed, Khadija S.
A1 Lambisia, Arnold L.
A1 de Laurent, Zaydah R.
A1 Mburu, Maureen W.
A1 Ong’era, Edidah M.
A1 Morobe, John M.
A1 Otieno, Edward
A1 Azali, Hamza Abdou
A1 Abdallah, Kamal Said
A1 Diarra, Abdoulaye
A1 Yahaya, Ali Ahmed
A1 Athanasius, Dratibi Fred
A1 Moeletsi, Nicksy Gumede
A1 Tsofa, Benjamin
A1 Bejon, Philip
A1 Borus, Peter
A1 Nokes, D. James
A1 Ochola-Oyier, Isabella
YR 2021
UL http://medrxiv.org/content/early/2021/04/13/2021.04.08.21254321.abstract
AB Phylogenetic analysis of six SARS-CoV-2 genomes collected from the Comoros islands confirmed local circulation of the 501Y.V2 variant of concern during the country’s first major SARS-CoV-2 wave in January 2021. These findings demonstrate the importance of SARS-CoV-2 genomic surveillance and have implications for ongoing COVID-19 control strategies on the islands.Article summary line Circulation of SARS-CoV-2 501Y.V2 variant of concern in the Comoros Islands during a major COVID-19 infection wave in January 2021Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported two National Institute for Health Research (NIHR) grants (project references 17/63/82 and 16/136/33) using UK aid from the UK Government to support global health research, the UK Foreign, Commonwealth and Development Office and Wellcome Trust (grant# 220985). The views expressed in this publication are those of the authors and not necessarily those of NIHR, the Department of Health and Social Care, Foreign Commonwealth and Development Office, Wellcome Trust or the UK government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The genomes generated were part of a regional collaborative COVID-19 public health rapid response. This manuscript therefore provides context on the genome data already available on GISAID. The whole genome sequencing study protocol was reviewed and approved by the Scientific and Ethics Review Committee (SERU) that sits at the Kenya Medical Research Institute (KEMRI) headquarters in Nairobi (SERU # 4035).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe six genomes have been deposited in GISAID (Accession numbers EPI_ISL_1323658 - EPI_ISL_1323663).